beluuga.ai

Overview

Pharmaceutical

Kubota Pharmaceutical Holdings Co.,Ltd.

Kubota Pharmaceutical Holdings is an ophthalmic medical solutions company focused on the development and commercialization of innovative drugs and medical devices to preserve and restore vision for patients with eye diseases worldwide. The company's key pipeline includes Kubota Glass, a wearable myopia control device utilizing its proprietary Active Stimulation technology, eyeMO, a home-based remote retinal monitoring device, and emixustat hydrochloride, a small-molecule compound targeting Stargardt disease and diabetic retinopathy. Following the relocation of its R&D base from the United States to Japan in 2024, the company is advancing both medical device and pharmaceutical programs with a mission to eliminate blindness.

Market Cap

¥9.57B

US$61.0M

¥8.00B

US$51.0M

Stock¥59▼-1.67%

US$1 = ¥156.80 (2026-10-23)

LTM EV/EBITDA

—

LTM EV/EBIT

LTM PER

LTM PBR

6.0

Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-26.1%pt

Oct 24, 25 – Oct 23, 26StockTOPIX

1Feb 12, 26FY guidance raised, revenue growth outlook +40%

MC → EV Bridge

AI Briefing

Generating insights…

Performance & Balance

Revenue 5Y (¥B)

EBITDA 5Y (¥B)

Net Income 5Y (¥B)

Capital Structure

99%

EquityD/E 0.01xDebt

Liquidity vs Debt 5Y (¥B)▲ Net Cash

CashInv. Sec.Debt

Shareholders

Top 10 hold 41.9%

as of 2026-06-30 · Source: Annual Securities Report

Ryo KUBOTA

27.89%

Kubota Asset Management Co., Ltd.

9.33%

BNYM SA/NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE (Standing Proxy: MUFG Bank, Ltd.)

0.95%

BNP PARIBAS LONDON BRANCH FOR PRIME BROKERAGE CLEARANCE ACC FOR THIRD PARTY (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)

0.72%

NOMURA INTERNATIONAL PLC A/C JAPAN FLOW (Standing Proxy: Nomura Securities Co., Ltd.)

0.63%

Morgan Stanley MUFG Securities Co., Ltd.

0.57%

Rakuten Securities, Inc. (Joint Account)

0.47%

SBI SECURITIES Co., Ltd.

0.46%

BCSL CLIENT RE BBPLC NYBR (Standing Proxy: Barclays Securities Japan Limited)

0.46%

JPMorgan Securities Japan Co., Ltd.

0.41%

Management

4 officers

Ryo KUBOTA

Director, Representative Director, Chairman, President and Chief Executive Officer

Jun 2002 Founded Acucela Inc.; Director Jun 2002 President, Chief Executive Officer and Principal Accounting Officer, Acucela Inc. Apr 2005 Chairman of the Board, Acucela Inc. Jun 2014 Visiting Professor, School of Medicine, Keio University May 2015 Chairman, President and Chief Executive Officer, and Director (current), Acucela Inc. (now Kubota Vision Inc.) Dec 2015 Representative Director, Chairman, President and Chief Executive Officer, the Company Dec 2016 Director, Representative Executive Officer, Chairman, President and Chief Executive Officer, the Company Apr 2023 Director, Representative Director, Chairman, President and Chief Executive Officer, the Company (current) Feb 2024 Representative Director, Chairman, President and Chief Executive Officer, Kubota Vision Japan K.K. (current) Significant concurrent positions: Chairman, President and Chief Executive Officer and Director, Kubota Vision Inc.; Representative Director, Chairman, President and Chief Executive Officer, Kubota Vision Japan K.K.

1966-10-18

Yuki NAKAGAWA

Outside Director, Audit and Supervisory Committee Member

Apr 2007 Joined Daiwa SMBC Securities Co., Ltd. (now Daiwa Securities Co. Ltd.) Apr 2010 Joined Masterpiece Group Co., Ltd. Jan 2014 Director, Masterpiece Group Co., Ltd. Oct 2023 Representative Director, Clearda Co., Ltd. (current) Apr 2025 Outside Director, Audit and Supervisory Committee Member, the Company (current) Significant concurrent position: Representative Director, Clearda Co., Ltd.

1982-11-08

Masaaki FUJIWARA

Outside Director, Audit and Supervisory Committee Member

Apr 1987 Joined Chugai Pharmaceutical Co., Ltd. Dec 2000 Joined PwC Consulting LLC Dec 2003 Joined Quintiles Transnational Japan K.K. Feb 2005 President and Representative Director, Kaiomu Bioscience Inc. Mar 2017 Director, Baika Therapeutics Inc. (current) Jun 2017 Joined Tsukuba Global Innovation Promotion Organization (General Incorporated Association) Oct 2017 Representative Director and Chief Operating Officer, S'UIMIN Inc. Dec 2019 Representative Director and President, S'UIMIN Inc. Feb 2021 Part-time Lecturer, One Earth Guardians Development Organization, Graduate School of Agricultural and Life Sciences, The University of Tokyo (current) Jan 2023 Office Director, One Earth Guardians Office (General Incorporated Association) (current) Apr 2023 Executive Manager, Rin Institute Inc.; Chief Strategy Officer, Myorage Inc. Jun 2023 Representative Director, Rin Institute Inc. (current) Apr 2025 Outside Director, Audit and Supervisory Committee Member, the Company (current) Significant concurrent positions: Director, Baika Therapeutics Inc.; Part-time Lecturer, One Earth Guardians Development Organization, Graduate School of Agricultural and Life Sciences, The University of Tokyo; Office Director, One Earth Guardians Office (General Incorporated Association); Representative Director, Rin Institute Inc.

1961-08-28

Taishi SHIBUYA

Outside Director, Audit and Supervisory Committee Member

Apr 2013 Joined KVH Co., Ltd. (Colt Technology Services Co., Ltd.) Mar 2015 Joined Yumenosora Holdings Co., Ltd. Apr 2019 Joined MIXI, Inc. Jul 2022 Representative Director, Shibuya Capital Group Co., Ltd. (current) Apr 2025 Outside Director, Audit and Supervisory Committee Member, the Company (current) Significant concurrent position: Representative Director, Shibuya Capital Group Co., Ltd.

1988-09-05

Large Shareholding Reports

Evo Fund

2026-07-14

8.19%→4.32%

Evo Fund

2026-07-08

6.18%→8.19%

Evo Fund

2026-07-06

8.37%→6.18%

Evo Fund

2026-07-06

8.73%→8.37%

Correction filing (name/detail fix only) — ratio carried over from the original filing

Evo Fund

2026-07-02

8.73%→8.37%

Evo Fund

2026-06-23

9.73%→8.73%

Evo Fund

2026-06-10

10.83%→9.73%

Evo Fund

2026-06-01

11.87%→10.83%

Evo Fund

2026-05-18

12.88%→11.87%

Evo Fund

2026-05-01

13.93%→12.88%

Evo Fund

2026-04-23

15.04%→13.93%

Evo Fund

2026-04-15

16.10%→15.04%

Evo Fund

2026-04-06

17.19%→16.10%

Evo Fund

2026-03-27

18.35%→17.19%

Evo Fund

2026-03-24

19.43%→18.35%

Evo Fund

2026-03-18

20.88%→19.43%

Evo Fund

2026-03-16

22.11%→20.88%

Evo Fund

2026-03-12

24.17%→22.11%

Evo Fund

2026-03-11

26.49%→24.17%

Evo Fund

2026-03-10

30.17%→26.49%

Evo Fund

2026-03-09

28.05%→30.17%

Evo Fund

2026-03-05

30.17%→28.05%

Evo Fund

2026-01-13

28.05%→30.17%

Evo Fund

2026-01-09

30.17%→28.05%

Evo Fund

2026-01-05

30.17%

Ryo KUBOTA

2025-12-23

30.57%→41.41%

Correction filing (name/detail fix only) — ratio carried over from the original filing

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-12-23

30.57%→41.41%

Annual report (as of 2026-06-30): 27.89%

NOMURA INTERNATIONAL PLC

2025-10-07

4.97%→1.20%

Barclays Capital Securities Ltd.

2025-09-19

0.01%→1.07%

NOMURA INTERNATIONAL PLC

2025-09-19

4.97%

Ryo KUBOTA

2025-09-10

26.20%→21.71%

Correction filing (name/detail fix only) — ratio carried over from the original filing

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-09-10

28.56%→26.20%

Correction filing (name/detail fix only) — ratio carried over from the original filing

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-09-10

24.58%→30.57%

Correction filing (name/detail fix only) — ratio carried over from the original filing

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-09-09

28.56%→26.20%

Annual report (as of 2026-06-30): 27.89%

Barclays Bank PLC

2025-09-09

12.58%→5.70%

Ryo KUBOTA

2025-09-09

26.20%→21.71%

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-09-09

21.71%→24.58%

Annual report (as of 2026-06-30): 27.89%

Ryo KUBOTA

2025-09-09

24.58%→30.57%

Annual report (as of 2026-06-30): 27.89%

Barclays Bank PLC

2025-08-28

13.59%→12.58%

Barclays Bank PLC

2025-07-31

14.62%→13.59%

Disclosures

No disclosures

Primary Source Filings

EDINET

2026-10-23

Securities Registration Statement

Kubota Pharmaceutical Holdings Co.,Ltd.

Try the full product

Kubota Pharmaceutical Holdings Co.,Ltd.

Try the full product

More Japanese companies in Pharmaceutical